Komori
GNI Group (2160) · InitiativeFirst stated

Approval Obtained for Esbriet 200 mg Capsules

First written in FY2016-Q3. . Latest entry: FY2016-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Acquisition of marketing approval for 200 mg アイスーリュイ capsulesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2016-Q3First statedAnnual report

    「In August 2016, Beijing Continent obtained a new manufacturing and marketing approval from the CFDA for 200 mg Etuary capsules (Chinese name: 艾思瑞®) as a treatment for idiopathic pulmonary fibrosis (IPF).」

    The company obtained manufacturing and marketing approval for 200 mg Etuary capsules in August 2016, improving dosing options for physicians and convenience for patients.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for GNI Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.